nach oben

Erschienen in:

2020 | OriginalPaper | Buchkapitel

28. Medikamentöse Therapie der CED bei Kindern und Jugendlichen

verfasst von : Klaus-Michael Keller

Erschienen in: Chronisch-entzündliche Darmerkrankungen

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Für die Therapie der CED im Kindes- und Jugendalter gibt es zahlreiche klinische Leitlinien, um eine für alle Versorgungsstufen gleichwertige, evidenzbasierte und qualitativ hochstehende Behandlung zu gewährleisten. Als wesentliche Unterschiede zwischen erwachsenen und pädiatrischen Patienten zeichnen sich bislang die in der Regel stärkere Inflammation und Ausdehnung von CU und MC bei Kindern ab. Verzögerungen im Längenwachstum und in der Pubertätsentwicklung kommen beim MC in der Pädiatrie regelmäßig vor. Daher hat die initiale exklusive Ernährung mit Elementardiät eine herausragende Bedeutung. Zentrale Therapieziele sind heute nicht mehr nur Symptomfreiheit sondern möglichst auch mukosale Heilung der CED. Zum Einsatz kommen die in der Erwachsenenmedizin geläufigen Medikamente, bei hoher Krankheitsaktivität früh immunmodulierende oder gar Biologika. Kinder und Jugendliche mit CED sollen trotz ihrer chronischen Erkrankung eine normale körperliche und psychosoziale Reifung mit der Möglichkeit einer ihren Fähigkeiten entsprechenden Schulbildung und normalem Berufs- und Familienleben als Erwachsene erreichen. Weitere Ziele sind Akzeptanz der Erkrankung, optimale Therapieadhärenz und Vermeidung einer Überbehandlung.

Abarbanel DN, Seki SM, Davies Y et al (2013) Immunmodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol 33:397–406PubMed

Abdullah BA, Gupta SK, Croffie JM et al (2002) The role of esophagogastroduodenoscopy in the initial evaluation of childhood inflammatory bowel disease: a 7-year study. J Pediatr Gastroenterol Nutr 35:636–640PubMed

Afzal NA, Addai S, Fagbemi A (2002) Refeeding syndrome with enteral nutrition in children. A case report, literature review and clinical guidelines. Clin Nutr 21:515–520PubMed

Akobeng AK, Thomas AG (2007) Enteral nutrition for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 18:3–CD005984

Akobeng AK, Thomas AG (2010) Refeeding syndrome following exclusive enteral nutritional treatment in Crohn‘ s disease. J Pediatr Gastroenterol Nutr 51:364–366PubMed

Aloi M, Di Nardo G, Conte F et al (2010) Methotrexate in pediatric ulcerative colitis: a retrospective survey at a single tertiary referral centre. Aliment Pharmacol Ther 32:1017–1022PubMed

Aloi M, D’Arcangelo G, Pofi F et al (2013) Presenting features and disease course of pediatric ulcerative colitis. J Crohns Colitis 7:e509–e515PubMed

Aloi M, Di Nardo G, Romano G et al (2015) Magnetic resonance enterography, small-intestine contrast US, and capsule endoscopy to evaluate the small bowel in pediatric Crohn’s disease: a prospective, blinded, comparison study. Gastrointest Endosc 81:420–427PubMed

Aloi M, Birimberg-Schwartz L, Buderus S et al (2016a) Treatment options and outcomes of pediatric IBDU compared with other IBD subtypes. A retrospective multicenter study from the IBD Porto Group of ESPGHAN. Inflamm Bowel Dis 22:1378–1383PubMed

Aloi M, D’Arcangelo G, Bramuzzo M et al (2016b) Effect of early versus late azathioprine therapy in pediatric ulcerative colitis. Inflamm Bowel Dis 22:1647–1654PubMed

Ashton JJ, Versteegh HP, Batra A et al (2016) Colectomy in pediatric ulcerative colitis: a single center experience of indications, outcomes, and complications. J Pediatr Surg 51:277–281PubMed

Ashworth LA, Billett A, Mitchell P et al (2012) Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm Bowel Dis 18:838–843PubMed

Baldassano R, Colletti RB, Cucchiara S et al (2013) 41 serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease. Develop registry data. Gastroenterology 144(5 Suppl 1):5–11

Barclay AR, Russell RK, Wilson ML et al (2009) Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. J Pediatr 155:421–426PubMed

Behrens R (2006) Chronisch-entzündliche Darmerkrankungen im Kindes- und Jugendalter, 2. Aufl. UNIMED Verlag, Bremen

Belli DC, Seidman E, Bouthilier L et al (1988) Chronic intermittent elemental diet improves growth failure in children with Crohn’s disease. Gastroenterology 94:603–610PubMed

Benninga MA, Nurko S, Faure C et al (2016) Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology 150:1443–1455

Benkov KJ, Rosh JR, Schwerenz AH et al (1994) Cyclosporine for the treatment of fulminant ulcerative colitis in children. J Pediatr Gastroenterol Nutr 19:290–294PubMed

Bermejo F, Garrido E, Chaparro M et al (2012) Efficacy of different therapeutic options for spontaneous abdominal abscesses in Crohn’s disease: Are antibiotics enough? Inflamm Bowel Dis 18:1509–1514PubMed

Birimberg-Schwartz L, Zucker DM, Akriv A et al (2017) Development and validation of diagnostic criteria for IBD subtypes with an emphasis on IBD-Unclassified in children. A multicenter study from the Pediatric IBD Porto group of ESPGHAN. J Crohns Colitis 11:1078–1084PubMed

Borrelli O, Bascietto C, Viola F et al (2004) Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig Liver Dis 36:342–347PubMed

Borrelli O, Cordischi I, Cirulli M et al (2006) Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease. A randomized controlled open-label trial. Clin Gastroenterol Hepatol 4:744–753PubMed

Bousvaros A, Kirschner BS, Werlin SL et al (2000) Oral tacrolimus treatment of severe colitis in children. J Pediatr 137:794–799PubMed

Buderus S, Scholz D, Behrens R et al (2015) Inflammatory bowel disease in pediatric patients – characteristics of newly diagnosed patients from the CEDATA-GPGE registry. Dtsch Ärztebl Int 112:121–127PubMedPubMedCentral

Canani RB, Tanturri de Horatio L, Terrin G et al (2006) Combined use of non-invasive tests is useful in the initial diagnosic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr 42:9–15PubMed

Cassinotti A, Actis GC, Duca P et al (2009) Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 104:2760–2767PubMed

Cezard JP, Munck A, Mouterde O et al (2009) Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn’s disease: a multicenter, double-blind, randomized, placebo-controlled trial. Gastroenterol Clin Biol 33:31–40PubMed

Choshen S, Finnamore H, Auth MK et al (2016) Corticosteroid dosing in pediatric acute severe ulcerative colitis: a propensity score analysis. J Pediatr Gastroenterol Nutr 63:58–64PubMed

Cohen SA, Gralnek IM, Ephrath H et al (2008) Capsule endoscopy may reclassify pediatric inflammatory bowel disease. A historical analysis. J Pediatr Gastroenterol Nutr 47:31–36PubMed

Cohen SA, Ephrath H, Lewis JD et al (2012) Pediatric capsule endoscopy: a single center, 5-year retrospective review of the small bowel and patency capsules. J Pediatr Gastroenterol Nutr 54:409–413PubMed

Cohen S, Martinez-Vinson C, Aloi M, Pediatric IBD Porto Group of ESPGHAN et al (2017) CMV infection in pediatric severe ulcerative colitis – a multicenter study from the Pediatric IBD porto Group of ESPGHAN. Pediatr Infect Dis J 36:197–201

Conrad MA, Stein RE, Maxwell EC et al (2016) Vedolizumab therapy in severe pediatric inflammatory bowel disease. Inflamm Bowel Dis 22:2425–2431PubMed

Crandall W, Hyams J, Kugathasan S et al (2009) Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr 49:183–190PubMed

Cucchiara S, Escher JC, Hildebrand H et al (2009) Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J Pediatr Gastroenterol Nutr 48:257–267PubMed

Day AS, Whitten KE, Lemberg DA et al (2006) Exclusive enteral feeding as primary therapy for Crohn’s disease in Australian children and adolescents. A feasible and effective approach. J Gastroenterol Hepatol 21:1609–1614PubMed

Day AS, Gulati AS, Patel N et al (2018) The role of combination therapy in pediatric inflammatory bowel disease: a clinical report from NASPGHAN. J Pediatr Gastroenterol Nutr 66:361–368PubMed

Deneau MR, El-Matary W, Valentino PL et al (2017) The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration. Hepatology 66:518–527PubMed

De Bie CI, Buderus S, Sandhu BK et al (2012a) Diagnostic workup of paediatric patients with inflammatory bowel disease in Europe: results of a 5-year audit of the EUROKIDS registry. J Pediatr Gastroenterol Nutr 54:374–380PubMed

De Bie CI, Escher JC, de Ridder L (2012b) Antitumor necrosis factor treatment for pediatric inflammatory bowel diease. Inflamm Bowel Dis 18:985–1002PubMed

De Ridder L, Turner D, Wilson DC et al (2014) Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the Porto pediatric IBD group. Inflamm Bowel Dis 20:291–300PubMed

Di Nardo G, Oliva S, Ferrari F et al (2011) Usefulness of wireless capsule endoscopy in paediatric inflammatory bowel disease. Dig Liver Dis 43:220–224PubMed

Dinesen LC, Walsh AJ, Protic MN et al (2010) The pattern and outcome of acute severe colitis. J Crohns Colitis 4:431–437PubMed

Dotson JL, Hyams JS, Markowitz J et al (2010) Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr 51:140–145PubMed

Dubinsky MC, Lamothe S, Yang HY et al (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118:705–713PubMed

Dubinsky MC, Ofman JJ, Urman M et al (2001) Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol 96:758–765PubMed

Dziechciarz P, Horvath A, Shamir R et al (2007) Meta-analysis: enteral nutrition in active Crohn’s disease in children. Aliment Pharmacol Ther 26:795–806PubMed

Eickstaedt JB, Killpack L, Tung J et al (2017) Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents. Pediatr Dermatol 34:253–260PubMed

El-Matary W, Stefanovici C, van Caeseele P et al (2018) Detection of Cytomegalovirus in colonic mucosa of children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 67:221–224PubMed

Escher JC, The European Collaborative Research Group on Budesonide in Paediatric IBD (2004) Budesonide versus prednisolone for the treatment of active Crohn’s disease in children: a randomised, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 16:47–54PubMed

Escher JC, IBD Working Group of ESPGHAN (2005) Inflammatory bowel disease in children and adolescents: recommendations for DIAGNOSIS – The Porto Criteria. J Pediatr Gastroenterol Nutr 41:1–7

Fagerberg UL, Lööf L, Myrdal U et al (2005) Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 40:450–455PubMed

Faiman A, Mutalib M, Moylan A et al (2014) Standard versus rapid food reintroduction after exclusive enteral nutritional therapy in paediatric Crohn’s disease. Eur J Gastroenterol Hepatol 26:276–281PubMed

Faure C, Belarbi N, Mougenot JF et al (1997) Ultrasonographic assessment of inflammatory bowel disease in children: comparison with ileocolonoscopy. J Pediatr 130:147–151PubMed

Feagan BG, Chande N, MacDonald JK (2013) Are there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from Cochrane reviews. Inflamm Bowel Dis 19:2031–2040PubMed

Ferry GD, Kirschner BS, Grand RJ et al (1993) Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J Pediatric Gastroenterol Nutr 17:32–38

Friedlander JAI, Liu QY, Sahn B et al (2017) NASPGHAN capsule endoscopy clinical report. J Pediatr Gastroenterol Nutr 64:485–494PubMed

Fritscher-Ravens A, Scherbakov P, Bufler P et al (2009) The feasibility of wireless capsule endoscopy in detecting small intestinal pathology in children under the age of 8 years: a multicenter European study. Gut 58:1467–1472PubMed

Frivolt K, Schwerd T, Werkstetter KJ et al (2014) Repeated exclusive enteral nutrition in the treatment of paediatric Crohn’s disease: predictors of efficacy and outcome. Aliment Pharmacol Ther 39:1398–1407PubMed

Fuentes D, Torrente F, Keady S et al (2003) High-dose azathioprine in children with inflammatory bowel disease. Aliment Pharmacol Ther 17:913–921PubMed

Gerich ME, Quiros JA, Marcin JP et al (2010) A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. J Crohns Colitis 4:546–555PubMed

Ghosh S, Drummond HE, Ferguson A (1998) Neglect of growth and development in the clinical monitoring of children and teenagers with inflammatory bowel disease: review of case reports. BMJ 317:120–121PubMedPubMedCentral

Gjuladin-Hellon T, Gordon M, Iheozor-Ejiofor Z, Akobeng AK (2019) Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2019 Jun 20;6(6):CD008414

Gralnek IM, Cohen SA, Ephrath H et al (2012) Small bowel capsule endoscopy impacts diagnosis and management of pediatric inflammatory bowel disease: a prospective study. Dig Dis Sci 57:465–471PubMed

Greenberg GR, Feagan BG, Martin F et al (1994) Canadian inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn’s disease. N Engl J Med 331:836–841PubMed

Greener T, Klang E, Yablecovitch D et al (2016) The impact of magnetic resonance enterography and capsule endoscopy on the re-classification of disease in patients with known Crohn’s disease: a Prospective Israeli IBD Research Nucleus (IIRN) Study. J Crohns Colitis 10:525–531PubMedPubMedCentral

Griffiths A, Koletzko S, Sylvester F et al (1993) Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn’s disease. J Pediatr Gastroenterol Nutr 17:186–192PubMed

Grossi V, Lerer T, Griffiths A et al (2015) Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn’s disease. Clin Gastroenterol Hepatol 13:1748–1756PubMed

Grossman AB, Noble AJ, Mamula P et al (2008) Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger. Inflamm Bowel Dis 14:750–755PubMed

Hashkes PJ, Becker ML, Cabral DA et al (2014) Methotrexate. New uses for an old drug. J Pediatr 164:231–236PubMed

Harms HK, Bloomer R, Bertele-Harms R-M et al (1994) A paediatric Crohn’s disease activity index (PCDAI). Is it useful? Acta Paediatr 395:22–26

Henker J, Müller S, Laas MW et al (2008) Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z Gastroenterol 46:874–875PubMed

Heuschkel RB, Menache CC, Megerian JT et al (2000) Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr 31:8–15PubMed

Heyman MB, Kirschner BS, Gold BD et al (2005) Children with early-onset inflammatory bowel disease: analysis of a pediatric IBD consortium registry. J Pediatr 146:35–40PubMed

Heyman MB, Kierkus J, Spenard J et al (2010) Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. Inflamm Bowel Dis 16:1931–1939PubMedPubMedCentral

Ho S, Church P, Sharma A et al (2016) Intensification of infliximab induction regimen improves response rate in steroid-refractory pediatric ulcerative colitis. Gastroenterology 150(4 suppl 1):131–132

Hofmekler T, Bertha M, McCracken C et al (2017) Infliximab optimization based on therapeutic drug monitoring in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 64:580–585PubMed

Horneff G (2013) Update on biologicals for treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther 13:361–376PubMed

Hommel KA, Denson LA, Baldassano RN (2011) Oral medication adherence and disease severity in pediatric inflammatory bowel disease. Eur J Gastroenterol Hepatol 23:250–254PubMedPubMedCentral

Hourigan SK, Oliva-Hemker M (2016) Fecal microbiota transplantation in children: a brief review. Pediatr Res 80:2–6PubMed

Hyams JS, Ferry DG, Mandel FS et al (1991) Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr 12:439–447PubMed

Hyams JS, Wyzga N, Kreutzer DL et al (1997) Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. J Pediatr Gastroenterol Nutr 24:289–295PubMed

Hyams JS, Crandall W, Kugathasan S et al (2007) Induction and maintenance Infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 132:863–873PubMed

Hyams JS, Lerer T, Griffiths A et al (2009) Long-term outcome of maintenance infliximab therapy in children with Crohn’s disease. Inflamm Bowel Dis 15(6):816–822PubMed

Hyams JS, Lerer T, Griffiths A et al (2010) Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol 105:1430–1436PubMed

Hyams JS, Lerer T, Mack D et al (2011) Outcome following thiopurine use in children with ulcerative colitis. A prospective multicenter registry study. Am J Gastroenterol 106:981–987PubMed

Hyams JS, Griffiths A, Markowitz J et al (2012a) Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology 143:365–374PubMed

Hyams J, Damaraju L, Blank M et al (2012b) Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 10:391–399e1PubMed

Hyams JS, Di Lorenzo C, Saps M et al (2016) Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 150:1456–1468

Hyams JS, Davis S, Mack DR et al (2017a) Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study. Lancet Gastroenterol Hepatol 2:855–868PubMedPubMedCentral

Hyams JS, Chan D, Adedokun OJ et al (2017b) Subcutaneous golimumab in pediatric ulcerative colitis: pharmocokinetics and clinical benefit. Inflamm Bowel Dis 23:2227–2237PubMed

Ihekweazu FD, Kellermayer R (2014) Allopurinol: a useful adjunct to thiopurine therapy for pediatric ulcerative colitis in the biologic era. J Pediatr Gastroenterol Nutr 59:22–24PubMed

Jacobstein DA, Markowitz JE, Kirschner BS et al (2005) Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 11:442–446PubMed

Jakobsen C, Bartek J, Weaver V et al (2011) Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease – a population-based study. Aliment Pharmacol Ther 34:1217–1224PubMed

Kamm MA, Sandborn WJ, Gassul M et al (2007) Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 132:66–75PubMed

Kaplan GG, Ng C (2017) Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 152:313–321PubMed

Karolewska-Bochenek K, Dziekiewicz M, Banaszkiewicz A (2017) Budesonide MMX in pediatric patients with ulcerative colitis. J Crohns Colitis 11:1402PubMed

Keller K-M (2010) Transition bei Jugendlichen mit CED. Monatsschr Kinderheilkd 158:738–744

Keller K-M, Büsching U (2018) Chronische Bauchschmerzen. Schwerpunktheft Psychosomatik im Kindes- und Jugendalter. BVKJ, Magdeburg, S 47–51

Kempinska A, Benchimol El, Mack A et al (2011) Short-course ondansetron for the prevention of methotrexate-induced nausea in children with Crohn disease. J Pediatr Gastroenterol Nutr 53:389–393PubMed

Kennedy NA, Rhatigan E, Arnott ID et al (2013) A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Aliment Pharmacol Ther 38:1255–1266PubMed

Kennedy NA, Kalla R, Warner B et al (2014) Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther 40:1313–1323PubMedPubMedCentral

Khan KJ, Ullman TA, Ford AC et al (2011) Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 106:661–673PubMed

Kierkus J, Iwanczak B, Wegner A et al (2015) Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease. J Pediatr Gastroenterol Nutr 60:580–653PubMed

Kirschner BS (1998) Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 115:813–821PubMed

Koletzko S, Niggemann B, Arato A et al (2012) Diagnostic approach and management of cow’s-milk protein allergy in infants and children: ESPGHAN GI committee practical guidelines. J Pediatr Gastroenterol Nutr 55:221–229PubMed

Konidari A, Anagnostopoulos A, Bonnett LJ et al (2014) Thiopurine monitoring in children with inflammatory bowel disease: a systematic review. Br J Clin Pharmacol 78:467–476PubMedPubMedCentral

Kotlyar DS, Lewis JD, Beaugerie L et al (2015) Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 13:847–858e4 quiz: e48–50PubMed

Kronman MP, Zaoutis TE, Haynes K et al (2012) Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics 130:794–803

Kruis W, Schutz E, Fric P et al (1997) Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11:853–858PubMed

Kruis W, Fric P, Pokrotnieks J et al (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53:1617–1623PubMedPubMedCentral

Kudo T, Nagata S, Ohtani K et al (2011) Pulse steroids as induction therapy for children with ulcerative colitis. Pediatr Int 53:974–979PubMed

Kugathasan S, Werlin SL, Martinez A et al (2000) Prolonged duration of response to infliximab in early but not late pediatric Crohn’s disease. Am J Gastroenterol 95:3189–3194PubMed

Kugathasan S, Saubermann LJ, Smith L et al (2007a) Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 56:1696–1705PubMedPubMedCentral

Kugathasan S, Nebel J, Skelton JA et al (2007b) Body mass index in children with newly diagnosed inflammatory bowel disease. Observations from two multicenter North American inception cohorts. J Pediatr 151:523–527PubMed

Kunde S, Pham A, Bonczyk S et al (2013) Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 56:597–601PubMed

Laghi A, Borrelli O, Paolantonio P et al (2003) Contrast enhanced magnetic resonance imaging of the terminal ileum in children with Crohn’s disease. Gut 52:393–397PubMedPubMedCentral

Lahdenne P, Wikström AM, Aalto K et al (2010) Prevention of acute adverse events related to infliximab infusions in pediatric patients. Arthritis Care Res 62:785–790

Larsen MD, Qvist N, Nielsen J et al (2016) Use of anti-TNF alpha agents and time to first-time surgery in paediatric patients with ulcerative colitis. J Crohns Colitis 10:650–656PubMed

Lawrence IC, Baird A, Lightower D et al (2017) Efficacy of rectal tacrolimus for induction therapy in patients with resistant ulcerative proctitis. Clin Gastroenterol Hepatol 15:1248–1255PubMed

Ledder O, Assa A, Levine A et al (2017) Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-centre experience from the Paediatric IBD Porto group of ESPGHAN. J Crohns Colitis 11:1230–1237PubMed

Lee CH, Tasker N, La Hei E et al (2014) Raised tacrolimus level and acute renal injury associated with acute gastroenteritis in a child receiving rectal tacrolimus. Clin J Gastroenterol 7:238–242PubMed

Lee D, Baldassano RN, Otley AR et al (2015) Comparative effectiveness of nutritional and biological therapy in North American Children with active Crohn’s disease. Inflamm Bowel Dis 21:1786–1793PubMed

Levine A, Weizman Z, Broide E et al (2003) A comparison of budesonide and prednisolone for the treatment of active paediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 36:248–252

Levine A, Turner D (2011) Combined azithromycin and metronidazole therapy is effective in inducing remission in paediatric Crohn’s disease. J Crohns Colitis 5:222–226PubMed

Levine A, de Bie CI, Turner D et al (2013) Atypical disease phenotypes in pediatric ulcerative colitis: 5-year analyses of the EUROKIDS Registry. Inflamm Bowel Dis 19:370–377PubMed

Levine A, Koletzko S, Turner D et al (2014) ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 58:795–806PubMed

Levine A, Yerushalmi B, Kori M et al (2017) Mesalamine enemas for induction of remission in oral mesalamine-refractory paediatric ulcerative colitis. A prospective cohort study. J Crohns Colitis 11:970–974PubMed

Levine A, Wine E, Assa A et al (2019) Crohn’s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology 157:440–450

Lewis JD, Abreu MT (2017) Diet as a trigger or therapy for inflammatory bowel diseases. Gastroenterology 152:398–414e6PubMed

Lionetti P, Bronzini F, Salvestrini C et al (2003) Response to infliximab is related to disease duration in paediatric Crohn’s disease. Aliment Pharmacol Ther 18:425–431PubMed

Losurdo G, Iannone A, Contaldo A et al (2015) Escherichia coli Nissle 1917 in ulcerative colitis treatment: systematic review and meta-analysis. J Gastrointestin Liver Dis 24:499–505PubMed

Louis E, Mary JY, Vernier-Massouille G et al (2012) Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142:63–70PubMed

Mack DR, Langton C, Markowitz J et al (2007) Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics 119:1113–1119PubMed

Malik S, Ahmed SF, Wilson ML et al (2012) The effects of anti-TNF-alpha treatment with adalimumab on growth in children with Crohn’s disease. J Crohns Colitis 6:337–344PubMed

Markowitz J, Grancher K, Kohn N et al (2000) A multicenter trial of 6-mercaptopurine and prednisolone in children with newly diagnosed Crohn’s disease. Gastroenterology 119:895–902PubMed

Marshall JK, Irvine EJ (1997) Rectal corticosteroids versus alternative treatment in ulcerative colitis. A meta-analysis. Gut 40:775–781PubMedPubMedCentral

Marshall WA, Tanner JM (1969) Variations in pattern of pubertal changes in girls. Arch Dis Child 44:29lff

Marshall WA, Tanner JM (1970) Variations in pattern of pubertal changes in boys. Arch Dis Child 45:13ff

Marteau P, Probert CS, Lindgren S et al (2005) Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54:960–965PubMedPubMedCentral

Martinelli M, Strisciuglio C, Veres G, Porto IBD Working Group of ESPGHAN (2014) Clostridium difficile and pediatric inflammatory bowel disease. A prospective, comparative, multicenter, ESPGHAN study. Inflamm Bowel Dis 20:2219–2225PubMed

Mehanna HM, Moledina J, Travis J (2008) Refeeding syndrome: what it is, and how to prevent and treat it. BMJ 336:1495–1498PubMedPubMedCentral

Mezoff E, Mann EA, Hart KW et al (2011) Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population. J Pediatr Gastroenterol Nutr 52:437–441PubMedPubMedCentral

Miele E, Shamir R, Aloi M et al (2018) Nutrition in paediatric inflammatory bowel disease: a position paper on behalf of the Porto IBD Group of ESPGHAN. J Pediatr Gastroenterol Nutr 66:687–708PubMed

Mieli-Vergani G, Vergani D, Baumann U et al (2018) Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN Hepatology Committee Position Statement. J Pediatr Gastroenterol Nutr 66:345–360PubMed

Muniyappa P, Gulati R, Mohr F et al (2009) Use and safety of rifaximin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 49:222–226

Narula N, Fine M, Colombel JF et al (2015) Systematic review: sequential rescue therapy in severe ulcerative colitis: do the benefits outweigh the risks? Inflamm Bowel Dis 21:1683–1694PubMed

Nagata S, Shimizu T, Kudo T et al (2010) Efficacy and safety of pulse steroid therapy in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease. Digestion 81:188–192PubMed

Navas-Lopez VM, Blasco Alonso J, Serrano Nieto MJ et al (2014) Oral tacrolimus for pediatric steroid-resistant ulcerative colitis. J Crohns Colitis 8:64–69PubMed

Nikfar S, Rahimi R, Rezaie A et al (2009) A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci 54:1157–1170PubMed

Nguyen TV, Nguyen TM, Lachaux A et al (2013) Usefulness of thiopurine metabolites in predicting azathioprine resistance in pediatric IBD patients. J Clin Pharmacol 53:900–908PubMed

Ogata H, Matsui T, Nakamura M et al (2006) A randomised dose finding study of oral tacrolimus (FK 506) therapy in refractory ulcerative colitis. Gut 55(9):1255–1262PubMedPubMedCentral

Oliva S, Di Nardo G, Ferrari F et al (2012) Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther 35:327–334PubMed

Oliva S, Cucchiara S, Spada C et al (2014) Small bowel cleansing for capsule endoscopy in paediatric patients. A prospective randomised single-blind study. Dig Liver Dis 46:51–55PubMed

Oliva-Hemker M, Hutfless S, Al Kazzi ES et al (2015) Clinical presentation and five-year therapeutic management of very early-onset inflammatory bowel disease in a large North American cohort. J Pediatr 167(527–532):e1–e3

Oliva S, Thomson M, de Ridder L et al (2018) Endoscopy in Pediatric Inflammatory Bowel Disease. A Position Paper on Behalf of the Porto IBD Group of ESPGHAN. J Pediatr Gastroenterol Nutr 67:414–430PubMed

Oshitani N, Kamata N, Ooiso R et al (2003) Outpatient treatment of moderately severe active ulcerative colitis with pulsed steroid therapy and conventional steroid therapy. Dig Dis Sci 48:1002–1005PubMed

Osterman MT, Kundu R, Lichtenstein GR et al (2006) Associations of 6-thioguanine nucleotide levels and inflammatory bowel disease activity. A meta-analysis. Gastroenterology 130:1047–1053PubMed

Pant C, Anderson MP, Deshpande A et al (2013) Health care burden of Clostridium difficile infection in hospitalized children with inflammatory bowel disease. Inflamm Bowel Dis 19:1080–1085PubMed

Pascarella F, Martinelli M, Miele E et al (2009) Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 154:854–858PubMed

Pfeffer-Gik T, Levine A (2014) Dietary clues to the pathogenesis of Crohn’s disease. Dig Dis 32:389–394PubMed

Ponsioen CY (2015) Diagnosis, differential diagnosis, and epidemiology of primary sclerosing cholangitis. Dig Dis 33(suppl 2):134–139PubMed

Probert CS, Dignass AU, Lindgren S et al (2014) Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements of quality of life. J Crohns Colitis 8:200–207PubMed

Rajwal SR, Puntis JWL, McClean P et al (2004) Endoscopic rectal sparing in children with untreated ulcerative colitis. J Pediatr Gastroenterol Nutr 38:66–69PubMed

Rahhal RM, Bishop WP (2008) Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis 14:1678–1682PubMed

Rembacken BJ, Snelling AM, Hawkey PM et al (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354:635–639PubMed

Rodrigues AF, Johnson T, Davies P et al (2007) Does polymeric formula improve adherence to liquid diet therapy in children with active Crohn’s disease? Arch Dis Child 92:767–770PubMedPubMedCentral

Romano C, Comito D, Famiani A et al (2010) Oral tacrolimus (FK 506) in refractory paediatric ulcerative colitis. Aliment Pharmacol Ther 31:676–677PubMed

Rosenberg W, Ireland A, Jewell DP (1990) High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol 12:40–41PubMed

Rosh JR, Lerer T, Markowitz J et al (2009) Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn’s disease. Am J Gastroenterol 104:3042–3049PubMed

Ross SC, Strachan J, Russell RK et al (2011) Psychosocial functioning and health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 53:480–488PubMed

Rubio A, Pigneur B, Garnier-Lengliné H et al (2011) The efficacy of exclusive nutritional therapy in paediatric Crohn’s disease, comparing fractionated oral vs. continuous enteral feeding. Aliment Pharmacol Ther 33:1332–1339PubMed

Ruemmele FM, Targan SR, Levy G et al (1998) Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 115:822–825PubMed

Ruemmele FM, Lachaux A, Cezard JP et al (2009) Efficacy of infliximab in pediatric Crohn’s disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis 15:388–394PubMed

Ruemmele FM, Veres G, Kolho KL et al (2014) Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis 8:1179–1207PubMed

Rufo PA, Denson LA, Sylvester FA et al (2012) Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr 55:93–108PubMedPubMedCentral

Russell RK, Wilson ML, Loganathan S et al (2011) A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther 33:946–953PubMed

Sandborn WJ, Danese S, D’Haens G et al (2015) Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther 41:409–418PubMedPubMedCentral

Sawczenko A, Sandhu BK (2003) Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 88:995–1000PubMedPubMedCentral

Schechter A, Griffiths A, Gana JC et al (2015) Early endoscopic, laboratory and clinical predictors of poor disease course in paediatric ulcerative colitis. Gut 64:580–588PubMed

Shaoul R, Brown S, Day AS (2018) Reasoning beyond the potential use of exclusive enteral nutrition and other specified diets in children with ulcerative colitis. J Pediatr Gastroenterol Nutr 66:378–382PubMed

Shaw SY, Blanchard JF, Bernstein CN (2010) Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 105:2687–2692PubMed

Sigall-Boneh R, Pfeffer-Gik T, Segal I et al (2014) Partial enteral nutrition with a Crohn’s disease exclusion diet is effective for induction of remission in children and young adults with Crohn’s disease. Inflamm Bowel Dis 20:1353–1360PubMed

Singh S, Nagpal SJ, Murad MH et al (2014) Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 12:210–218PubMed

Singh N, Rabizadeh S, Jossen J et al (2016) Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis 22:2121–2126PubMed

Spray C, Debelle GD, Murphy MS (2001) Current diagnosis, management and morbidity in paediatric inflammatory bowel disease. Acta Paediatr 90:400–406PubMed

Stocco G, Martelossi S, Arrigo S et al (2017) Multicentric case-control study on azathioprine dose and pharmacokinetics in early-onset pediatric inflammatory bowel disease. Inflamm Bowel Dis 23:628–634PubMed

Suskind DL, Wahbeh G, Burpee T et al (2013) Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. J Pediatr Gastroenterol Nutr 56:277–279PubMedPubMedCentral

Suskind DL, Singh N, Nielson H et al (2015) Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 60:27–29PubMed

Sutherland LR, May GR, Shaffer EA (1993) Sulfasalazine revisited: a meta-analysis of 5-Aminosalicylic acid in the treatment of ulcerative colitis. Ann Int Med 118:540–549PubMed

Thanarj S, Hamlin PJ, Ford AC (2010) Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis. Aliment Pharmacol Ther 32:1297–1306

Thayu M, Leonard MB, Hyams JS et al (2008) Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn’s disease: results of the REACH study. Clin Gastroenterol Hepatol 6:1378–1384PubMed

Timmer A, Behrens R, Buderus S et al (2011a) Childhood onset inflammatory bowel disease: predictors of delayed diagnosis from CEDATA German-Language pediatric inflammatory bowel disease registry. J Pediatr 158:467–473PubMed

Timmer A, Preiss JC, Motschall E et al (2011b) Psychological intervention for treatment of inflammatory bowel disease. Cochrane Database of Syst Rev 16(2):CD006913

Travis SP, Danese S, Kupcinskas L et al (2014) Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 63:433–441PubMed

Truffinet O, Martinez-Vinson C, Guerriero E et al (2017) Tacrolimus exerts only a transient effectiveness in refractory pediatric Crohn disease: a case series. J Pediatr Gastroenterol Nutr 64:721–725PubMed

Turner D, Grossman AB, Rosh J et al (2007a) Methotrexate following unsuccessfull thiopurine therapy in pediatric Crohn’s disease. Am J Gastroenterol 102:2804–2812PubMed

Turner D, Walsh CM, Steinhart AH et al (2007b) Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and meta-analysis. Clin Gastroenterol Hepatol 5:103–110PubMed

Turner D, Otley AR, Mack D et al (2007c) Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 133:423–432PubMed

Turner D, Walsh CM, Benchimol EI et al (2008) Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 57:331–338PubMed

Turner D, Hyams J, Markowitz J et al (2009a) Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis 15:1218–1223PubMed

Turner D, Seow CH, Greenberg GR et al (2009b) A systematic prospective comparison of noninvasive activity indices in ulcerative colitis. Clin Gastroenterol Hepatol 7:1081–1088PubMed

Turner D, Mack D, Leleiko N et al (2010) Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 138:2282–2291PubMed

Turner D, Griffiths AM (2011) Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis 17:440–449PubMed

Turner D, Griffiths AM, Veerman G et al (2013) Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. Clin Gastroenterol Hepatol 11:1460–1465PubMed

Turner D, Yerushalmi B, Kori M et al (2017) Once- versus twice-daily mesalazine to induce remission in paediatric ulcerative colitis. A randomised controlled trial. J Crohns Colitis 11:527–533PubMed

Turner D, Ruemmele FM, Orlanski-Meyer E et al (2018a) Management of paediatric ulcerative colitis, part 1: ambulatory care- an evidence-based guideline from ECCO and ESPGHAN. J Pediatr Gastroenterol Nutr 67:257–291PubMed

Turner D, Ruemmele FM, Orlanski-Meyer E et al (2018b) Management of paediatric ulcerative colitis, part 2: acute severe colitis- an evidence-based consensus guideline from ECCO and ESPGHAN. J Pediatr Gastroenterol Nutr 67:292–310PubMed

Uhlig HH (2013) Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut 62:1795–1785PubMed

Uhlig HH, Schwerd T, Koletzko S et al (2014) The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 147:990–1007e3PubMedPubMedCentral

Vahabnezhad E, Rabizadeh S, Dubinsky MC et al (2014) A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. Inflamm Bowel Dis 20:606–613PubMedPubMedCentral

Valentino PL, Church PC, Shah PS et al (2014) Hepatotoxicity caused by methotrexate therapy in children with inflammatory bowel disease.: a systematic review and meta-analysis. Inflamm Bowel Dis 20:47–59PubMed

Vandenplas Y, Veereman G, van der Werff Ten Bosch J et al (2015) Fecal microbial transplantation in early-onset colitis: caution advised. J Pediatr Gastroenterol Nutr 61:e12–14PubMed

Van Dijkhuizen EH, Wulffraat NM (2014) Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review. Pediatr Rheumatol Online J 12:51PubMedPubMedCentral

Van Limbergen J, Russel RK, Drummond HE et al (2008) Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 135:1114–1122

Van Rheenen PF, van de Vijver E, Fidler V (2010) Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: a diagnostic meta-analysis. BMJ 341:c3369PubMedPubMedCentral

Van Rheenen PF, Aloi M, Biron IA et al (2017) European Crohn’s and colitis organisation topical review on transitional care in inflammatory bowel disease. J Crohns Colitis 11:1032–1038PubMed

Van Shaik FD, van Oijen MG, Smeets HM et al (2012) Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 61:235–240

Vasseur F, Gower-Rousseau C, Vernier-Massouille G et al (2010) Nutritional status and growth in pediatric Crohn’s disease: a population-based study. Am J Gastroenterol 105:1893–1900PubMed

Vernier-Massouille G, Balde M, Salleron J et al (2008) Natural history of pediatric Crohn’s disease. A population-based cohort study. Gastroenterology 135:1106–1113PubMed

Volonaki E, Mutalib M, Kiparissi E et al (2015) Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis. Eur J Gastroenterol Hepatol 27:1425–1428PubMed

Vora R, Finnamore HE, Crook K et al (2016) Clinical experience of use of high-dose intravenous methylprednisolone in children with acute moderate to severe colitis. J Pediatr Gastroenterol Nutr 63:51–57PubMed

Wang SL, Wang ZR, Yang CQ et al (2012) Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med 4:1051–1056PubMedPubMedCentral

Wang Y, Parker CE, Bhanji T et al (2016a) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 4:CD000543PubMed

Wang Y, Parker CE, Feagan BG et al (2016b) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 5:CD000544

Watson S, Pensabene L, Mitchell P et al (2011) Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis 17:22–29PubMed

Weinstein TA, Levine M, Pettel MU et al (2003) Age and familiy history at presentation of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 37:609–613PubMed

Werkstetter KJ, Pozza SB, Filipiak-Pittroff B et al (2011) Long-term development of bone geometry and muscle in pediatric inflammatory bowel disease activity. Am J Gastroenterol 106:988–998PubMed

Whitten KE, Leach ST, Bohane TD et al (2010) Effect of exclusive enteral nutrition on bone turnover in children with Crohn’s disease. J Gastroenterol 45:399–405PubMed

Wilschanski M, Sherman P, Pencharz P et al (1996) Supplementary enteral nutrition maintains remission in paediatric Crohn’s disease. Gut 38:543–548PubMedPubMedCentral

Winter HS, Krzeski P, Heyman MB et al (2014) High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis. J Pediatr Gastroenterol Nutr 59:767–772PubMedPubMedCentral

Zachos M, Tondeur M, Griffiths AM (2007) Enteral nutrition therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 1:Cd000542

Ziring DA, Wu SS, Mow WS et al (2007) Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr 45:306–311PubMed

Titel: Medikamentöse Therapie der CED bei Kindern und Jugendlichen
verfasst von: Klaus-Michael Keller
Verlag: Springer Berlin Heidelberg
Buch: Chronisch-entzündliche Darmerkrankungen
Print ISBN: 978-3-662-59103-1

Electronic ISBN: 978-3-662-59104-8

Copyright-Jahr: 2020
DOI: https://doi.org/10.1007/978-3-662-59104-8_28

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen